11th Annual Meeting of International Cytokine & Interferon Society
11th Annual Meeting of International Cytokine & Interferon Society
批准号:
10753947
负责人:
James K Turkson
金额:
$0.5万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-15 至 2024-07-31
关键词:
Allergic DiseaseAmazeApplications GrantsApplied ResearchArthritisAuthorization documentationAutoimmune DiseasesAutoimmunityAwardB-LymphocytesBasic ScienceBiological MarkersBiologyBiotechnologyBudgetsCOVID-19COVID-19 impactChronic DiseaseClinicClinical ResearchCollaborationsCommunicable DiseasesCountryCytokine Network PathwayDataDevelopmentDiabetes MellitusDisciplineDiseaseEventFeedbackFinancial SupportFutureGoalsGovernmentGreeceHIVHawaiiHealthHost DefenseHumanHybridsImmuneInfectionInflammationInflammatoryInstitutionInterferonsInternationalIntuitionKidney DiseasesKnowledgeLightningLobbyingLong COVIDLoveMalignant NeoplasmsMediatingModern MedicineMolecularNatural ImmunityParentsParticipantPersonsPharmacologic SubstanceProteinsQualifyingReportingResearchResearch PersonnelRheumatoid ArthritisRoleScientistSocietiesStudentsT-LymphocyteTherapeuticTimeTranslational ResearchTravelUnderrepresented MinorityUpdateVaccinationViral CancerVirus DiseasesWorkadaptive immunitycancer immunotherapycareercareer developmentcollaborative environmentcostcytokinedesigndigital platformexhibitionsflexibilityfundamental researchimmune activationimmunoregulationinhibitorinterestlive streammeetingsmultidisciplinarynew therapeutic targetnovelnovel therapeutic interventionnovel therapeuticspersonalized medicinepostersprecision medicineprogramsresponsesymposiumtargeted cancer therapytherapeutic targetvirtualvirtual platform
中文摘要
摘要
英文摘要
ABSTRACT
The purpose of this application is to request financial support for Cytokines 2023: 11th Annual Meeting of the
International Cytokine & Interferon Society (ICIS), October,15-18, 2023, with llivestream and on-demand virtual
access through October 29, 2023. This Annual Meeting helps bridge the gap between the scientists performing
basic research on molecular and cellular mechanisms of immune cell activation and function with those working
to develop this knowledge into novel therapies. The 11th edition comes at a time when cytokine biology, cytokine
biomarkers and cytokine therapeutics are revolutionizing modern medicine, providing novel treatments for a wide
variety of diseases ranging from lethal inflammatory, autoimmune and allergic diseases, to viral infections and
cancer. This year’s theme is “Cytokines and interferons in the precision medicine era”, focusing on the latest
developments on cytokine biology in relation to immune regulation, host damage and disease, and the latest
progress on cytokines/cytokine inhibitors as novel therapeutics in the clinic.
A variety of topics will be covered by leaders in the field in the plenary and parallel sessions such as innate
immunity and host defense, adaptive immunity, cytokines in T and B cell responses to vaccination, in Long
COVID, HIV and novel targeted therapies from cancer immunotherapy to novel therapeutics in autoimmunity.
Since a major goal of the meeting is to promote interactions between scientists and clinicians working in basic,
translational or applied research, ample opportunity will be given to poster networking sessions to present the
latest advances elated to cytokine research, biomarkers and therapeutics. Greater understanding of mechanisms
of disease and novel concepts for therapy have and will continue to emerge from interdisciplinary gatherings
where advances can be presented and discussed by established and trainee scientists.
The meeting will focus on cytokines in personalized medicine and will provide an opportunity for updates on the
development of novel therapeutic interventions in these fields and help spur international collaborations among
the meeting participants. Although meeting participants will have primary interests in infectious diseases, cancer
and immune-mediated diseases, the program integrates speakers on the periphery of Cytokine and Interferon
research to help bridge these disciplines. This interdisciplinary environment is particularly interesting for early
career researchers who are not only focused on their own field of research but are beginning to think about the
wider implications of their work. Our goal is to increase attendance of early career investigators and trainees and
also to achieve higher representation of underrepresented minorities at all levels of career development.
Online presentations will consist of livestreamed video presentations for all speakers who give their permission
to be recorded, to benefit virtual attendees as well as in-person attendees to access content from parallel
sessions or missed presentations. ICIS Meetings Committee and Council have decided that included virtual
access even without travel restrictions, makes the Annual Meeting more inclusive and sustainable.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses to hirsutinolides
-
批准号:9443606
-
项目类别:
-
资助金额:$50.27万
-
财政年份:2017
-
负责人:James K Turkson
-
依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
-
批准号:10098001
-
项目类别:
-
资助金额:$54.99万
-
财政年份:2017
-
负责人:James K Turkson
-
依托单位:
STAT3, G6PD and TrxR as underlying mechanisms for antitumor responses tohirsutinolides
-
批准号:10005721
-
项目类别:
-
资助金额:$26.28万
-
财政年份:2017
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8370490
-
项目类别:
-
资助金额:$48.94万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8676474
-
项目类别:
-
资助金额:$46.78万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8770667
-
项目类别:
-
资助金额:$7.81万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8856165
-
项目类别:
-
资助金额:$48.06万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:8519385
-
项目类别:
-
资助金额:$42.39万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Salicylic acid-based small-molecule Stat3 inhibitors for anticancer therapy
-
批准号:9069481
-
项目类别:
-
资助金额:$48.06万
-
财政年份:2012
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7526222
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:8115186
-
项目类别:
-
资助金额:$22.39万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7685297
-
项目类别:
-
资助金额:$18.2万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
Therapeutic Application of Novel Stat3 Inhibitors in Breast and Pancreatic Cancer
-
批准号:7903970
-
项目类别:
-
资助金额:$21.15万
-
财政年份:2008
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:6870436
-
项目类别:
-
资助金额:$11.25万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7336340
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7018427
-
项目类别:
-
资助金额:$24.28万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7216350
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7123704
-
项目类别:
-
资助金额:$17.34万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
STATs as a Novel Approach to Cancer Therapy
-
批准号:7547751
-
项目类别:
-
资助金额:$23.53万
-
财政年份:2005
-
负责人:James K Turkson
-
依托单位:
海外基金